Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial

SIMPLE SUMMARY: This is the first phase II study of high dose rabeprazole repurposing (1.5 mg/kg bid, three days a week) combined with metronomic capecitabine (mCAP), 1500 mg/daily, in gastrointestinal cancer, aimed at evaluating the activity and safety of high-dose proton pump inhibitor in combinat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Roberto, Michela, Romiti, Adriana, Mazzuca, Federica, Milano, Annalisa, D’Antonio, Chiara, Lionetto, Luana, Falcone, Rosa, Strigari, Lidia, Simmaco, Maurizio, Fais, Stefano, Marchetti, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690608/
https://ncbi.nlm.nih.gov/pubmed/33105819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113084
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky